Skip to main content

Efficient prediction & monitoring of TNFα blocker therapy


We are offering a new biomarker that enables the reliable and efficient prediction & monitoring of anti-TNFα therapies, whose efficacy, up to date, cannot be properly addressed.

This innovation is based on the determination in blood of IL-22BP to predict the performance of TNFα-blockers on a patient, allowing the optimization of time and costs, as well as reducing common and undisired side effects of this therapy.

We suggest a new tool to fill the existing gap and extending the concept of personalized medicine in a wide range of diseases, which are treated with TNFα-blockers.


The pathogenesis of Inflammatory Bowel Disease (IBD) remains still unclear, yet it has been closely related to the inflammatory response.

Current therapies target TNFα to inhibit its inflammatory effects. The success of the therapy is monitored through observation of clinical symptoms and TNFα antibodies level. This yields a limited amount of information, since the effects of the treatment are only detectable with the development of the patient’s wellbeing.

This inefficient monitoring entails remarkable disadvantages for the patient and health system, due to the side effects and high costs associated to TNFα-blockers treatment.

We are presenting an innovative biomarker for the prediction & monitoring of the efficacy of anti-TNFα treatments, allowing its consistent use.


In relation to the inflammatory nature of IBD, our scientists have stablished a link between IL-22 and the evolution of IBD disease. Due to its proinflammatory effect, the control of IL-22 is of major importance for the patient.

IL-22BP regulates the function of the free interleukin. Its expression has been identified to be positively correlated to that of TNFα. It has been also proven that the expression of IL-22BP is not down-regulated in patients not responding to TNFα-blockers treatment.

Measurements of intestinal T-Cells IL-22BP expression in biopsies indicate a positive effect of the therapy by downregulation of the binding protein.

Based on this facts, we suggest the measurement of IL-22BP for predicting the effectiveness of the treatment and measuring the evolution of the disease in treated patients.

Our biomarker allows the early prediction of the effectiveness of the costly, lifelong treatment, thus adapting the therapy options to each patient. We bring IBD treatment one step closer to personalized medicine. Furthermore TNFα blockers are used in several other diseases, such as Psoriasis, potentially widen the usage of this biomarker.


The standard treatment of IBD patients based on TNFα blockers yields the expected therapy effects only in approximately 50% of the cases. Many others do not profit of this therapy yet suffer from its side effects.

Our innovation enables the optimisation anti-TNFα therapy in a number of aspects:

  • Treatment time
  • Treatment costs
  • Minimise related side effects


  • Inflammatory Bowel Disease treatment
  • Anti-TNFα therapy
  • Presonalized medicine


  • R&D Cooperation
  • Transfer of rights
  • Licensing


Dr. Francisco Blanco
Harburger Schloßstraße 6-12
21079 Hamburg




  • PCT PCT/EP2017/054218 anhängig


Pelczar et. al. Science, 2016, 254 (6310) doi: 10.1126/science.aah5903

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen